Orchestra BioMed Holdings (OBIO) Non Operating Investment Income (2021 - 2026)
Orchestra BioMed Holdings (OBIO) reported Non Operating Investment Income of -$100000.0 for Q1 2026, down 566.67% year-over-year from $21428.6 in Q1 2025, and down 766.67% on a QoQ basis from $15000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 6 years of Non Operating Investment Income data on file, last reported at -$100000.0 in Q1 2026.
- Quarterly Non Operating Investment Income fell 566.67% year-over-year to -$100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77000.0 (down 271.11% YoY) and the FY2025 annual result came in at $8000.0, down 87.1% from the prior year.
- Non Operating Investment Income eased to -$100000.0 in Q1 2026 per OBIO's latest filing, from $15000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $1.7 million in Q2 2022 and bottomed at -$314000.0 in Q3 2022.
- The 5-year median for Non Operating Investment Income is -$21000.0 (2025), against an average of $37529.4.
- Peak annual rise in Non Operating Investment Income reached 43269.27% in 2022, while the deepest fall reached 7883.84% in 2022.
- Tracing OBIO's Non Operating Investment Income over 5 years: stood at -$165000.0 in 2022, then plunged by 78.18% to -$294000.0 in 2023, then jumped by 84.35% to -$46000.0 in 2024, then surged by 132.61% to $15000.0 in 2025, then tumbled by 766.67% to -$100000.0 in 2026.
- Per Business Quant, the three latest OBIO Non Operating Investment Income figures stand at -$100000.0 (Q1 2026), $15000.0 (Q4 2025), and $29000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | -100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -100,000.00 |
| Mar 31, 2026 | -100,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Dec 31, 2024 | -46,000.00 |
| Dec 31, 2024 | -46,000.00 |
| Sep 30, 2024 | 121,000.00 |
| Sep 30, 2024 | 121,000.00 |
| Jun 30, 2024 | -15,000.00 |
| Jun 30, 2024 | -15,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | -294,000.00 |
| Dec 31, 2023 | -294,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Jun 30, 2023 | -61,000.00 |
| Jun 30, 2023 | -61,000.00 |
| Mar 31, 2023 | -27,000.00 |
| Mar 31, 2023 | -27,000.00 |
| Dec 31, 2022 | -165,000.00 |
| Dec 31, 2022 | -165,000.00 |
| Sep 30, 2022 | -314,000.00 |
| Sep 30, 2022 | -314,000.00 |
| Jun 30, 2022 | 1.73 Mn |
| Jun 30, 2022 | 1.73 Mn |
| Mar 31, 2022 | -220,000.00 |
| Mar 31, 2022 | -220,000.00 |
| Dec 31, 2021 | 4,034.00 |
| Dec 31, 2021 | 4,034.00 |
| Sep 30, 2021 | 4,034.00 |
| Sep 30, 2021 | 4,034.00 |
| Jun 30, 2021 | 3,989.00 |
| Jun 30, 2021 | 3,989.00 |
| Mar 31, 2021 | 3,946.00 |
| Mar 31, 2021 | 3,946.00 |